Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control

• Main Authors: Miriam Méndez-del Villar, Esperanza Martínez-Abundis, Rafael O. Preciado-Márquez, Manuel González-Ortiz
• Format: Article
• Language: English
• Published: Brazilian Society of Endocrinology and Metabolism 2017-02-01
• Series: Archives of Endocrinology and Metabolism
• Subjects: Diacerein; metformin; glycemic control; type 2 diabetes mellitus
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972017000200188&lng=en&tlng=en

ABSTRACT Objective To evaluate the effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control. Materials and methods A randomized, double-blind, placebo-controlled clinical trial was carried out on 12 patients with T2DM and inadequate glycemic control [glycated hemoglobin A1c (A1C) ≥ 7%] with metformin as monotherapy (≥ 1500 mg per day) for at least the previous 90 days. Fasting and postprandial glucose were measured before and after the pharmacological intervention. A1C, lipid profile, creatinine and uric acid were also evaluated. After randomization, all patients continued with their dose of metformin. Six subjects received placebo and the other six volunteers took diacerein. Data were tested using the Wilcoxon signed-rank, Mann-Whitney U and chi-square tests. The Institutional Ethics Committee approved the study protocol. Results After 90 days of diacerein as an add-on to metformin, there was a significant decrease in fasting glucose (196 ± 79 vs. 149 ± 70 mg/dL, p < 0.05), postprandial glucose (262 ± 99 vs. 187 ± 70 mg/dlL, p < 0.05) and A1C (8.4 ± 2.0 vs. 6.7 ± 1.7 %, p < 0.05). Conclusions Diacerein as an add-on to metformin in patients with T2DM improved their glycemic control.